Apple Hospitality REIT Bolsa (NYSE: APLE)

Últimas noticias sobre Apple Hospitality REIT (NYSE:APLE) Bolsa

Apple Hospitality REIT

Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.

Apple Hospitality REIT, Inc. Common Shares

Apple Hospitality REIT Inc

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) with a Buy and maintains $5.5 price target.

News

Price Target

Reiteration

Analyst Ratings

LPTX

HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $5.5 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and maintains $10 price target.

AFMD

HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target

UBS analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with a Buy rating and announces Price Target of $21.

Initiation

UBS Initiates Coverage On Telix Pharmaceuticals with Buy Rating, Announces Price Target of $21

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) with a Buy and lowers the price target from $32 to $30.

GNLX

HC Wainwright & Co. Maintains Buy on Genelux, Lowers Price Target to $30

BMO Capital analyst John Kim upgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Underperform to Market Perform and raises the price target from $19 to $21.

Upgrades

BMO Capital Upgrades Independence Realty Trust to Market Perform, Raises Price Target to $21

EYEN

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

POOL

Pool Corp shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Domino's Pizza shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Baird analyst Shrenik Kothari maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and raises the price target from $385 to $425.

PANW

Baird Maintains Outperform on Palo Alto Networks, Raises Price Target to $425

ULTA

Ulta Beauty shares are trading lower after Berkshire Hathaway cut its position in the stock.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) with a Buy and maintains $3 price target.

RNAZ

HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/66585980a3067c00012c48c0/david-roman">Goldman Sachs analyst David Roman </a>initiated coverage on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral rating and announced a price target of $108. HealthEquity shares closed at $95.70 on Thursday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with an Underperform rating and announced a price target of $25. Pfizer shares closed at $26.02 on Thursday. <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/insights/analyst-ratings/24/10/41494343/analyst-expectations-for-mastecs-future">Stifel analyst Brian Brophy</a> initiated coverage on EMCOR Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy rating and announced a price target of $600. EMCOR shares closed at $498.11 on Thursday. <a href="https://www.benzinga.com/quote/EME/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Harry Read initiated coverage on Insight Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) with a Buy rating and announced a price target of $220. Insight Enterprises shares closed at $152.63 on Thursday. See how other analysts view this stock.</li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with an Outperform rating and announced a price target of $190. Johnson &amp; Johnson shares closed at $151.87 on Thursday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png" alt="" class="wp-image-650063" style="width:716px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169.png 1196w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

NSIT

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Sol-Gel Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.13) by 92.31 percent. This is a 95.24 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $5.36 million which beat the analyst consensus estimate of $2.69 million by 99.29 percent. This is a 2.42K percent increase over sales of $213.00 thousand the same period last year.

SLGL

Sol-Gel Technologies Q3 EPS $(0.01) Beats $(0.13) Estimate, Sales $5.36M Beat $2.69M Estimate

Baird analyst Wesley Golladay maintains Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) with a Neutral and raises the price target from $26 to $29.

Baird Maintains Neutral on Kite Realty Gr Trust, Raises Price Target to $29

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Baird analyst Jack Allen maintains MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Outperform and lowers the price target from $8 to $4.

INKT

Baird Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $4

Citigroup analyst Beatrice Lam downgrades Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) from Buy to Neutral and lowers the price target from $2.3 to $0.5.

Downgrades

Citigroup Downgrades Gogoro to Neutral, Lowers Price Target to $0.5

HC Wainwright &amp; Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and maintains $8 price target.

PSTV

HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target

Baird analyst Joel Beatty maintains Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) with a Outperform and raises the price target from $6 to $7.

IMMP

Baird Maintains Outperform on Immutep, Raises Price Target to $7

"The CHMP's positive opinion marks an important milestone for patients in Europe with non-epithelioid mesothelioma, who experience worse survival outcomes than patients with epithelioid mesothelioma," said Dr. Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories. "The positive CHMP opinion moves us closer to offering a new first-line treatment option with a proven overall survival benefit for certain patients in the European Union with this difficult-to-treat cancer."

Merck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult  Patients With Unresectable Non-epithelioid Malignant Pleural Mesothelioma

Apple Hospitality Q3 2024 Earnings Preview

Here are the major earnings after the close today

Reports Q3 revenue $378.843M, consensus $380.15M. Justin Knight, Chief Executive Officer of Apple Hospitality, commented, "With slow but steady imp...

Apple Hospitality REIT reports Q3 MFFO 45c, consensus 45c

Apple Hospitality FFO of $0.45 in-line, revenue of $378.84M misses by $0.8M

Apple Hospitality Q3 FFO rises as leisure travel goes strong; updates guidance

Oppenheimer analyst Tyler Batory maintained a Buy rating on Apple Hospitality REIT (APLE – Research Report) today and set a price target of $17.00....

Oppenheimer Sticks to Its Buy Rating for Apple Hospitality REIT (APLE)

Apple Hospitality REIT, Inc. (APLE) Q3 2024 Earnings Call Transcript

Apple Hospitality REIT Inc ( ($APLE) ) has released its Q3 earnings. Here is a breakdown of the information Apple Hospitality REIT Inc presented to...

Apple Hospitality REIT Reports Q3 2024 Results

Apple Hospitality: My Top REIT For Income With Attractive Yield

A Decisive Realignment

ABCL

ACRE

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

ALAB

ANDE

AOMN

AOMR

AOSL

APLE

AQST

ATUS

AZPN

BCOV

BLDG

BWXT

BXMT

CDNA

CENX

CIMN

CIMO

CLLS

CMTG

COLD

CRGY

CRUS

CSTL

CUBE

EGHT

ELME

EQIX

FBRT

FREL

GQRE

HAUS

HAUZ

HDSN

HIMS

HOLX

HOMZ

ICHR

IFGL

ILMN

INDS

INSP

INVH

IRET

ITUB

KBWY

LINE

LSCC

METC

MFAN

MFAO

MITN

MITP

MITT

MORT

NAIL

NETL

NTST

NURE

NVTS

OTTR

PARR

PFFR

PLDGP

PLYM

PPTY

RDOG

REET

REGCO

REGCP

REIT

RIET

ROIC

ROOF

SACC

SACH

SBAC

SCCC

SCCD

SCCE

SCCF

SCCG

SCHH

SRVR

STWD

USRT

VICI

VIOO

VNORP

VRAI

WELL

XLRE

Press Releases

Apple Hospitality REIT Announces Monthly Distribution

Apple Hospitality REIT Acquires the Embassy Suites by Hilton Madison Downtown

Apple Hospitality REIT Reports Results of Operations for Second Quarter 2024

Apple Hospitality REIT Announces Dates for Third Quarter 2024 Earnings Release and Conference Call

Management

Whitestone REIT Continues Board Refreshment with Appointment of Two Independent Trustees

Apple Hospitality REIT Reports Results of Operations for Third Quarter 2024

Ashford Hospitality Trust Inc Common Stock

Ashford Hospitality Trust

Braemar Hotels & Resorts Inc. Common Stock

Braemar Hotels & Resorts

Chatham Lodging Trust (REIT) Common Shares of Beneficial Interest

Chatham Lodging

Diamondrock Hospitality Company Common Stock

Diamondrock Hospitality

Host Hotels & Resorts, Inc. - Common Stock

Host Hotels & Resorts

InnSuites Hospitality Trust Shares of Beneficial Interest

InnSuites Hospitality

Summit Hotel Properties, Inc. Common Stock

Summit Hotel Properties

Comments

Apple Hospitality REIT

Noticias

Últimas noticias sobre Apple Hospitality REIT (NYSE:APLE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL